| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.15.6.780 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC352758 |
| https://europepmc.org/articles/PMC352758?pdf=render | ||
| https://journals.asm.org/doi/pdf/10.1128/AAC.15.6.780 | ||
| P932 | PMC publication ID | 352758 |
| P698 | PubMed publication ID | 475363 |
| P2093 | author name string | J. J. Lipsky | |
| C. R. Smith | |||
| P. S. Lietman | |||
| P2860 | cites work | Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside | Q28318332 |
| Controlled Comparison of Amikacin and Gentamicin | Q28324094 | ||
| Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy | Q40694970 | ||
| Ototoxicity of Gentamicin in Man: A Survey and Controlled Analysis of Clinical Experience in the United States | Q50645402 | ||
| A Rapid Chemical Assay for Gentamicin | Q69158143 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 780-2 | |
| P577 | publication date | 1979-06-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity | |
| Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity | |||
| P478 | volume | 15 |
| Q40748729 | A clinical review of ototoxicity |
| Q33714230 | Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials |
| Q38919674 | Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review |
| Q38676819 | Aminoglycoside-induced hearing loss in humans |
| Q35806154 | Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing |
| Q39598341 | Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services |
| Q39856345 | Comparison of radioimmunoassay with a new immunofluorescent method (FIAX) for measuring tobramycin in serum |
| Q30371562 | Gentamicin-induced ototoxicity and nephrotoxicity vary with circadian time of treatment and entail separate mechanisms. |
| Q33725329 | In vitro evaluation of cefoperazone |
| Q28540814 | Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial. |
| Q42908869 | Management of Aminoglycosides in the Intensive Care Unit |
| Q40918381 | Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations |
| Q45006893 | Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides |
| Q34874579 | Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss |
| Q39818301 | Therapeutic initiatives for the avoidance of aminoglycoside toxicity |
| Q42268489 | Tobramycin therapy of serious infections. Pharmacological aspects and side effects |
| Q28361967 | Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides |
Search more.